Stockscreener 앱 받기
0.738
3.59%
0.0256
시간 외 거래:
.75
0.012
+1.63%
전일 마감가:
$0.7124
열려 있는:
$0.729
하루 거래량:
44,299
Relative Volume:
0.17
시가총액:
$34.57M
수익:
$10.85M
순이익/손실:
$-51.31M
주가수익비율:
-1.0014
EPS:
-0.737
순현금흐름:
$-40.15M
1주 성능:
-4.82%
1개월 성능:
-29.71%
6개월 성능:
-61.56%
1년 성능:
-69.38%
1일 변동 폭
$0.7017
$0.7498
1주일 범위
$0.69
$0.888
52주 변동 폭
$0.69
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
명칭
InspireMD Inc.
전화
972 3 6917691
주소
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.738 | 35.60M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Maxim Group | Buy |
| 2016-01-07 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 개시 | Oppenheimer | Outperform |
InspireMD Inc. 주식(NSPR)의 최신 뉴스
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementCore Business Growth - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD (NSPR) Gains 6% to $0.95 as Stock Approaches Critical $1.00 ResistanceHigh Conviction Picks - newsline.com
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares SlideEarnings Call Highlights - thelegaladvocate.com
InspireMD (NSPR) Slides 7.9% as Stock Tests Key Support Near $0.84RVOL Spike - The Legal Advocate
InspireMD (NSPR) Slides 8.4% to $0.87: Key Levels Under PressureEarnings Beat Stocks - newsline.com
InspireMD (NSPR) Q1 2026 Earnings: EPS Beat Despite Net Loss, Shares Dip 2.9%Post-Announcement Reaction - Newser
Paul Stuka to Retire from InspireMD Board, Will Not Seek Re‑election - TradingView
InspireMD (NSPR) chair Paul Stuka plans Board retirement in 2027 - Stock Titan
NSPR Q1 2026 Earnings: Loss Narrower Than Expected as InspireMD Advances Commercial PipelineProfit Growth Outlook - Newser
InspireMD CCO Shane Gleason sells $189,594 in stock By Investing.com - Investing.com Canada
InspireMD CCO Shane Gleason sells $189,594 in stock - Investing.com
InspireMD (NSPR) CCO auto-sells shares to cover RSU tax obligations - Stock Titan
InspireMD (NSPR) price target decreased by 13.33% to 4.42 - MSN
Nantahala reports 4.82M shares in InspireMD (NSPR) including convertibles - Stock Titan
Director Stuka increases InspireMD (NSPR) stake with 15,000-share buys - Stock Titan
Velan Capital holds 4.99% of InspireMD (NASDAQ: NSPR) via 2.35M shares - Stock Titan
TradingKey - TradingKey
InspireMD CEO Marvin Slosman buys $25,200 in company stock By Investing.com - Investing.com Australia
InspireMD Inc (NSPR) CEO Marvin Slosman Increases Stake with Rec - GuruFocus
NSPR: Endovascular stenting for carotid disease is accelerating, backed by best-in-class clinical results - TradingView
InspireMD CEO Marvin Slosman buys $25,200 in company stock - Investing.com UK
InspireMD Inc. (NSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.43%
자본화:
|
볼륨(24시간):